Clinical

With 1 biosimilar already approved in the US, the FDA has finally released draft guidelines for naming these new products.

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.

A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.

Both surveys and peer-reviewed research show patients like telehealth services. CVS' announcement comes after a successful pilot program showed a collaboration of telehealth and the retail clinics produced good results for patients.

A stepped care algorithm developed by scientists has the potential to manage blood pressure in patients who develop intolerance to guideline-based regimens.

It's time for employers to consider more than just the medical benefits but the pharmacy benefits when it comes to specialty pharmaceuticals, said Cheryl Larson, BA, vice president of the Midwest Business Group on Health.

The Biosimilars Council wants CMS to hold back on Medicare Part B reimbursement for biosimilars.

An article published in the Journal of Clinical Oncology finds that survivorship care plans may not greatly improve patient satisfaction with their care.

It's time to give the people what they want-real action to make pharmaceutical pricing more transparent, rational, and sustainable.

Restrictive prior authorization policies have made had a negative impact on schizophrenia patients, who tend to be an already-difficult population to treat, explained Dana Goldman, PhD.

A trigger built in patient EHRs can avoid follow-up delays in those at risk for developing certain types of cancers, a JCO study shows.

Aetna and the University of Chicago Medicine kicked off a value-based oncology medical home model in July this year in an effort to transition from fee-for-service to value-based care.

The primary care doctor's involvement in a patient's weight-loss program can significantly improve patient outcomes, a study published in Patient Education & Counseling has found.

The National Comprehensive Cancer Network has announced the development of another "price" calculator that will help stakeholders assess the relative "value" of available options.

In a study that will surely set off alarms, Kansas researcher Kyle Chapman found that those with a college degree gain more benefits from good diets and exercise than those without the same education.

The study published in Science Translational Medicine found that tissue stiffening in the breasts of obese women can drive the development of malignant disease.

Conducted by researchers at the Memorial Sloan Kettering Cancer Center, phase 2 results from a basket trial evaluated the efficacy of vemurafenib on nonmelanoma BRaf V600-mutated cancers in 122 patients across 23 global centers.

Research conducted at the University of Texas has identified an important role of psychological disorders in the early readmission of patients with chronic obstructive pulmonary disease.

Pelvic Floor Disorders (PFDs) affect tens of millions of women in the US alone, yet both provider and patient awareness remains low.

New resources are being directed toward precision medicine, particularly in cancer care. With that in mind, Evidence-Based Oncology, a publication of The American Journal of Managed Care, devotes its current issue to articles and commentaries on this growing field.

Evidence provided by a study published in The Lancet Oncology affirms that oral contraceptives provide long-term protection against endometrial cancer.

An article published in JAMA Oncology underscores the need for efforts to improve quality of life for cancer patients.

Analysis of results from the CHAARTED trial, published in the New England Journal of Medicine, has found that 6 cycles of chemotherapy (docetaxel) before androgen-deprivation therapy early in the treatment of metastatic prostate cancer significantly improved overall survival than treatment with ADT alone.